Epigral quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	705	607	+16.3%
EBITDA	179	163	+9.7%
EBITDA margin	25.4%	26.9%	−1.5 pts
Profit before tax	133	107	+24.8%
Net profit	99.7	161	−37.9%
EPS	₹23.12	₹37.25	−37.9%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	705	736	597	587	607	628	645	626	651	525	472	478	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	4.1	−0.6	5.6	1.7	8.3	3.4	3.9	5.6	2.4	1.5	2.5	1.0
	709	736	603	589	615	631	649	632	654	526	474	479
	430	410	413	349	318	323	329	331	339	273	276	241
	−37.1	14.9	−55.3	−21.4	0.9	5.7	3.7	1.9	19.9	−6.1	−28.5	31.0
	36.7	36.5	31.6	31.5	30.0	31.0	29.1	27.0	27.4	25.5	22.5	20.8
	7.2	15.8	11.0	21.8	23.4	11.8	−0.1	27.3	14.3	13.7	20.2	21.3
	42.9	41.7	42.8	42.3	41.5	34.0	32.9	32.3	33.5	30.4	30.9	31.5
	96.4	106	105	96.0	94.0	94.3	101	88.2	88.1	76.9	78.4	77.5
	576	625	548	519	508	500	496	507	523	413	400	423
	179	169	103	132	163	173	183	178	176	155	123	108
	136	127	60.0	90.1	122	139	150	146	143	125	91.9	76.4
Profit
	133	111	54.6	70.0	107	131	154	124	131	113	74.2	56.1
	133	111	54.6	70.0	107	131	154	124	131	113	74.2	56.1
	34.8	28.2	13.5	17.6	25.4	15.0	38.0	21.9	23.2	19.9	13.6	10.3
	−0.8	0.4	1.9	0.9	−79.1	29.4	12.0	22.0	21.9	16.2	11.3	7.6
	34.0	28.6	15.5	18.4	−53.7	44.4	50.0	43.9	45.1	36.2	24.9	17.9
	0.6	−1.0	−0.0	−0.3	0.3	0.3	0.1	0.8	−0.1	0.6	−0.2	−0.2
	99.7	81.0	39.1	51.2	161	86.9	104	81.3	85.9	77.3	49.1	38.0
	99.2	81.9	39.2	51.5	160	86.6	104	80.5	86.0	76.7	49.3	38.2
	0.0	0.6	−0.3	−0.1	−0.1	−0.1	−0.1	−0.1	−0.1	−0.6	0.1	0.1
	99.8	81.5	38.8	51.1	161	86.8	104	81.2	85.8	76.6	49.1	38.1
	99.7	81.0	39.1	51.2	161	86.9	104	81.3	—	77.3	49.1	38.0
Per share
	₹23.12	₹18.76	₹9.07	₹11.87	₹37.25	₹20.14	₹24.25	₹19.57	₹20.67	₹18.60	₹11.81	₹9.14
	₹23.12	₹18.76	₹9.07	₹11.87	₹37.25	₹20.14	₹24.25	₹19.57	₹20.67	₹18.60	₹11.81	₹9.14
Other comprehensive income — detail
	0.0	0.6	−0.3	−0.1	−0.1	−0.1	—	—	—	—	—	—
	0.0	0.8	−0.4	−0.2	−0.2	−0.1	−0.2	−0.2	−0.2	−1.0	0.1	0.1
	0.0	0.2	−0.1	−0.0	−0.0	−0.0	—	—	—	—	—	—
	—	—	—	—	—	—	−0.1	−0.1	−0.1	−0.3	0.0	0.0
	99.8	81.5	38.8	51.1	161	86.8	104	81.2	85.8	76.6	49.1	38.1
Per share — as-filed variants
	₹23.12	₹18.76	₹9.07	₹11.87	₹37.25	₹20.14	₹24.25	₹19.57	₹20.67	₹18.60	₹11.81	₹9.14
	₹23.12	₹18.76	₹9.07	₹11.87	₹37.25	₹20.14	₹24.25	₹19.57	₹20.67	₹18.60	₹11.81	₹9.14
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	312	311	239	260	287	299	312	294	292	258	224	206
	44.3%	42.3%	40.0%	44.2%	47.4%	47.6%	48.4%	46.9%	44.8%	49.1%	47.4%	43.1%
Adjusted (ex-exceptional items) — derived
	133	111	54.6	70.0	107	131	154	124	131	113	74.2	56.1
	99.7	81.0	39.1	51.2	161	86.9	104	81.3	85.9	77.3	49.1	38.0
	₹23.12	₹18.76	₹9.07	₹11.87	₹37.25	₹20.14	₹24.25	₹19.57	₹20.67	₹18.60	₹11.81	₹9.14

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

EPIGRAL₹907.30

Epigral Limited

· Chemicals

Annual Quarterly₹ CrorePeersYASHO GUJALKALI FCL FOSECOIND VISHNU TATVA GALAXYSURF JUBLCPLMcap ₹3,914 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	478.1	471.5	524.6	651.2	626.1	645.2	627.6	606.5	587.4	597.1	736.2	705.4
Other Income	1.0	2.5	1.5	2.4	5.6	3.9	3.4	8.3	1.7	5.6	-0.6	4.1
Total Income	479.2	474.0	526.2	653.6	631.6	649.1	631.0	614.8	589.1	602.7	735.6	709.5
Expenses
+ Cost of Materials Consumed	240.9	276.4	272.9	339.5	330.6	329.1	323.3	318.2	348.9	413.5	410.2	430.2
+ Changes in Inventories	31.0	-28.5	-6.1	19.9	1.9	3.7	5.7	0.9	-21.4	-55.3	14.9	-37.1
+ Employee Benefit Expense	20.8	22.5	25.5	27.4	27.0	29.1	31.0	30.0	31.5	31.6	36.5	36.7
+ Finance Costs	21.3	20.2	13.7	14.3	27.3	-0.1	11.8	23.4	21.8	11.0	15.8	7.2
+ Depreciation & Amortisation	31.5	30.9	30.4	33.5	32.3	32.9	34.0	41.5	42.3	42.8	41.7	42.9
+ Other Expenses	77.5	78.4	76.9	88.1	88.2	100.9	94.3	94.0	96.0	104.6	106.0	96.4
Total Expenses	423.0	399.8	413.3	522.5	507.2	495.6	500.0	508.1	519.2	548.1	625.1	576.3
EBITDA	107.9	122.8	155.4	176.4	178.4	182.5	173.4	163.4	132.4	102.7	168.6	179.2
EBIT	76.4	91.9	125.0	143.0	146.2	149.6	139.4	121.9	90.1	60.0	126.9	136.3
Profit
PBT before Exceptional Items	56.1	74.2	112.9	131.1	124.4	153.5	131.1	106.7	70.0	54.6	110.5	133.2
Pretax Income	56.1	74.2	112.9	131.1	124.4	153.5	131.1	106.7	70.0	54.6	110.5	133.2
+ Current Tax	10.3	13.6	19.9	23.2	21.9	38.0	15.0	25.4	17.6	13.5	28.2	34.8
+ Deferred Tax	7.6	11.3	16.2	21.9	22.0	12.0	29.4	-79.1	0.9	1.9	0.4	-0.8
Tax Expense	17.9	24.9	36.2	45.1	43.9	50.0	44.4	-53.7	18.4	15.5	28.6	34.0
+ Share of Associates & JVs	-0.2	-0.2	0.6	-0.1	0.8	0.1	0.3	0.3	-0.3	-0.0	-1.0	0.6
Net Income	38.0	49.1	77.3	85.9	81.3	103.6	86.9	160.7	51.2	39.1	81.0	99.7
+ Net Income — Continuing Ops	38.2	49.3	76.7	86.0	80.5	103.5	86.6	160.4	51.5	39.2	81.9	99.2
+ Other Comprehensive Income	0.1	0.1	-0.6	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.3	0.6	0.0
Total Comprehensive Income	38.1	49.1	76.6	85.8	81.2	103.5	86.8	160.6	51.1	38.8	81.5	99.8
Net Income to Common	38.0	49.1	77.3	—	81.3	103.6	86.9	160.7	51.2	39.1	81.0	99.7
Per Share
Basic EPS	9.14	11.81	18.60	20.67	19.57	24.25	20.14	37.25	11.87	9.07	18.76	23.12
Diluted EPS	9.14	11.81	18.60	20.67	19.57	24.25	20.14	37.25	11.87	9.07	18.76	23.12
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-0.1	-0.1	-0.1	-0.3	0.6	0.0
+ Items NOT to be Reclassified to P&L	0.1	0.1	-1.0	-0.2	-0.2	-0.2	-0.1	-0.2	-0.2	-0.4	0.8	0.0
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.0	-0.0	-0.0	-0.1	0.2	0.0
+ Tax on Items NOT to be Reclassified — alt tag	0.0	0.0	-0.3	-0.1	-0.1	-0.1	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	38.1	49.1	76.6	85.8	81.2	103.5	86.8	160.6	51.1	38.8	81.5	99.8
Per Share — as-filed variants
Basic EPS — Continuing Operations	9.14	11.81	18.60	20.67	19.57	24.25	20.14	37.25	11.87	9.07	18.76	23.12
Diluted EPS — Continuing Operations	9.14	11.81	18.60	20.67	19.57	24.25	20.14	37.25	11.87	9.07	18.76	23.12
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	206.3	223.6	257.8	291.9	293.6	312.5	298.7	287.5	259.9	239.0	311.1	312.3
Gross Margin %	43.14	47.43	49.15	44.82	46.89	48.43	47.59	47.40	44.24	40.02	42.27	44.28
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	56.1	74.2	112.9	131.1	124.4	153.5	131.1	106.7	70.0	54.6	110.5	133.2
Net Income Adj (tax-effected)	38.0	49.1	77.3	85.9	81.3	103.6	86.9	160.7	51.2	39.1	81.0	99.7
EPS Adj	9.14	11.81	18.60	20.67	19.57	24.25	20.14	37.25	11.87	9.07	18.76	23.12
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	41.6	41.6	41.6	41.6	41.6	43.1	43.1	43.1	43.1	43.1	43.1	43.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Epigral Q2 FY27 results date

Epigral (NSE: EPIGRAL) will announce its Q2 FY27 results (July–September 2026) on Monday, 2 November 2026, according to the board-meeting notice it filed on 26 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹99.7 crore, down 37.9% from ₹161 crore in Q1 FY26 and up 23.2% from ₹81 crore in Q4 FY26. Revenue from operations was ₹705 crore, up 16.3% year on year and down 4.2% from the previous quarter.

Board-meeting notice filed: 26 October 2026
Q2 FY26 results (a year earlier): 10 November 2025
Q1 FY27 results (the latest): 27 July 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 2 November 2026Monday · notice filed 26 Oct
Q1 FY27 net profit: ₹99.7 Cr−37.9% vs Q1 FY26+23.2% vs Q4 FY26
Q1 FY27 revenue: ₹705 Cr+16.3% vs Q1 FY26−4.2% vs Q4 FY26
Q1 FY27 operating margin: 19.3%−0.8 pts vs Q1 FY26+2.1 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹51.2 CrRevenue ₹587 Cr
Q1 FY27 EPS (basic): ₹23.12

Questions

When will Epigral announce its Q2 FY27 results?

On 2 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 26 October 2026). Last year it reported Q2 FY26 on 10 November 2025.

What will Epigral's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹51.2 crore and revenue from operations ₹587 crore. The latest quarter, Q1 FY27, had a net profit of ₹99.7 crore and revenue of ₹705 crore.

What were Epigral's Q1 FY27 results?

Consolidated net profit was ₹99.7 crore, down 37.9% from ₹161 crore in Q1 FY26 and up 23.2% from ₹81 crore in Q4 FY26. Revenue from operations was ₹705 crore, up 16.3% year on year and down 4.2% from the previous quarter.

How has Epigral's profit changed over the last four quarters?

Net profit by quarter: ₹51.2 crore in Q2 FY26, ₹39.1 crore in Q3 FY26, ₹81 crore in Q4 FY26 and ₹99.7 crore in Q1 FY27. That is ₹271 crore over the four quarters, down 37.3% from ₹433 crore in the four quarters before. Revenue from operations: ₹587 crore, ₹597 crore, ₹736 crore and ₹705 crore.

What was Epigral's net profit in FY26?

Consolidated net profit was ₹332 crore in FY26 (April 2025–March 2026), down 7.2% from ₹358 crore in FY25. It was ₹196 crore in FY24 and ₹353 crore in FY23: down 6.0% over three years, an average fall of 2.1% a year.

What was Epigral's revenue in FY26?

Revenue from operations was ₹2,527 crore in FY26 (April 2025–March 2026), down 0.9% from ₹2,550 crore in FY25. It was ₹1,929 crore in FY24 and ₹2,188 crore in FY23: up 15.5% over three years, 4.9% a year on average.

Where do these Epigral figures come from?

From Epigral's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.